论文部分内容阅读
目的:探讨吡柔比星为主联合化疗治疗老年非霍奇金淋巴瘤临床疗效。方法:我院2011年6月~2012年7月收治的90例老年非霍奇金淋巴瘤患者,将其随机平均分为A组和B组,各有患者45例。A组患者采用传统化疗方法 CHOP(环磷酰胺+阿霉素+长春新碱+泼尼松),B组患者采用以吡柔比星为主的CTOP的化疗方案。结果:B组患者疗效总缓解率为73.3%,不良反应率60%,B组患者疗效总缓解率为91.1%,不良反应率31.1%,2组相比差异均具有统计学意义(p<0.05)。结论:吡柔比星为主联合化疗治疗老年非霍奇金淋巴瘤疗效显著,患者经治疗后发生的不良反应较少,能有效提高患者的生活质量,值得临床应用推广。
Objective: To investigate the clinical efficacy of pirarubicin combined with chemotherapy in the treatment of elderly non-Hodgkin’s lymphoma. Methods: 90 elderly patients with non-Hodgkin’s lymphoma who were admitted to our hospital from June 2011 to July 2012 were randomly divided into group A and group B, with 45 patients in each group. Patients in group A received chemotherapy with CHOP (cyclophosphamide plus doxorubicin plus vincristine plus prednisone), while patients in group B received pirarubicin-based CTOP. Results: In group B, the overall response rate was 73.3% and the adverse reaction rate was 60%. The overall response rate was 91.1% and the rate of adverse reactions was 31.1% in group B. The differences between the two groups were statistically significant (p <0.05 ). Conclusion: The combination of pirarubicin and chemotherapy in the treatment of elderly non-Hodgkin’s lymphoma significant effect, the patients treated with fewer adverse reactions, can effectively improve the quality of life of patients, it is worth promoting the clinical application.